Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.

@article{Hoeppner2015DopamineDR,
  title={Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.},
  author={Luke Hilbert Hoeppner and Ying Wang and Anil K. Sharma and Naureen Javeed and Virginia P Van Keulen and Enfeng Wang and Ping Yang and Anja Christiane Roden and Tobias D Peikert and Juan Manuel Madrid Molina and Debabrata Mukhopadhyay},
  journal={Molecular oncology},
  year={2015},
  volume={9 1},
  pages={
          270-81
        }
}
We sought to determine whether Dopamine D2 Receptor (D2R) agonists inhibit lung tumor progression and identify subpopulations of lung cancer patients that benefit most from D2R agonist therapy. We demonstrate D2R agonists abrogate lung tumor progression in syngeneic (LLC1) and human xenograft (A549) orthotopic murine models through inhibition of tumor angiogenesis and reduction of tumor infiltrating myeloid derived suppressor cells. Pathological examination of human lung cancer tissue revealed… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Similar Papers

Loading similar papers…